This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Discovery Labs Holds Out Hope for Surfaxin

Discovery Laboratories (DSCO - Get Report) tried Monday to put a sunny face on the most recent regulatory setback for its infant lung drug Surfaxin, but in reality, there are few reasons for investors to smile.

In an update Monday, Discovery said that it believes it can respond to questions posed by the U.S. Food and Drug Administration within six to eight weeks, and that another Surfaxin review -- the FDA's fourth -- might only take 60 days to complete.

Discovery's optimism appears to be based on its own assessment of the Surfaxin approvable letter sent by the FDA Friday. The company also acknowledged Monday, however, that it hasn't met with regulators to go over the details of the approvable letter.

To believe in the best-case scenario laid out by Discovery management means having faith in a company that has failed, after three tries over several years, to gain U.S. regulatory approval for Surfaxin, a synthetically derived lung surfactant for the treatment of premature infants with respiratory distress syndrome.

Is there any reason to give Discovery the benefit of the doubt?

Discovery shares were gaining 33% in Monday trading after losing half their value Friday when the company announced that it failed again to convince the FDA that Surfaxin should receive final approval.

Manufacturing and quality control issues, particularly the latter, appear to be the continuing reason for the FDA's concerns. Monday, Discovery said it believes the company can reach an agreement with the FDA on some new tests to verify the stability and purity of Surfaxin.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
BMY $67.48 0.00%
DSCO $0.70 0.00%
GSK $42.26 0.00%
POZN $10.70 0.00%
AAPL $126.44 0.00%

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs